Company: CERO
Filing Date: 2025-12-05
Form Type: S-1
Source: 0001213900-25-118817
Chunk: 263

Company: CERO THERAPEUTICS HOLDINGS, INC.
Filing Date: 2025-12-05
Form: S-1
Chunk 263
---
:----|:--------------|----:|:----|:---------|-------:|:----|:-----------|
| Chris Ehrlich,                 
 Chief Executive Officer        |     | 10/01/2024 |     | 12/02/2024   |     |               | 1,278 |     |               |   — |     | $        | 200.00 |     | 09/30/2034 |
| Brian G. Atwood,               
 Former Chief Executive Officer |     | 10/01/2024 |     | 12/02/2024   |     |               |   254 |     |               |   — |     | $        | 200.00 |     | 09/30/2034 |
| Andrew “Al” Kucharchuk,        
 Chief Financial Officer        |     | 10/01/2024 |     | 10/01/2024   |     |               |    62 |     |               | 188 |     | $        | 200.00 |     | 09/30/2034 |
| Kristen Pierce, Ph.D.          
 Chief Development Officer      |     | 10/01/2024 |     | 10/01/2024   |     |               |    89 |     |               |  44 |     | $        | 200.00 |     | 09/30/2034 |

Employee Benefits and Equity Incentive Compensation Plan Equity Incentive Compensation We believe it is important to maintain a strong link between executive incentives and the creation of stockholder value. We believe performance and equity-based compensation for our executives to be an important component of maximizing stockholder value while, at the same time, attracting, motivating and retaining high-quality executives. Upon consummation of the Business Combination, we assumed options issued pursuant to the 2016 Plan, and we currently maintain the 2024 Plan and the 2024 ESPP. As of December 31, 2023, the 2016 Plan had options outstanding to purchase a total of 391 shares of common stock for a weighted average exercise price of $560.00 per share. On February 14, 2024, upon consummation of the Business Combination, these options were assumed by us and converted into options to purchase shares in CERo at a conversion rate of 0.064452 underlying shares per legacy share and a strike price calculated as